Background: Iron is a crucial component for sustaining life in living beings and plays a key role in the treatment of anaemia. This study evaluated the iron (II) content in different brands of iron-containing drugs commercially available in Ado-Ekiti, Nigeria. Methods: 15 pharmaceutical products, comprising tablets, capsules, and syrups, were procured from licensed pharmacies in AdoEkiti. Iron content was quantified by UV–visible spectrophotometry. Initially, ferrous ions (Fe²⁺) in the samples were reacted with 1,10phenanthroline under acidic conditions to form an orangered chelate exhibiting a maximum absorbance at 508 nm. Iron concentrations were then interpolated from a constructed standard Fe²⁺ calibration curve and compared with the British Pharmacopoeia (BP) and United States Pharmacopoeia (USP) assay limits for the iron salts. Results: Among the 15 samples analysed, syrups had the highest frequency, with 73.33% of the entire sample manufactured locally. In the assay test, 9 brands (2 tablets, 5 capsules, and 2 syrups), which constituted 60% of the samples, were found to have Fe2+ levels within the BP and USP limits. However, 40% of the analysed samples had iron content that fell outside the acceptable limits specified in the pharmacopoeias. Conclusion: The study's findings revealed discrepancies between the actual Fe2+ content and the claimed values across the various tested brands. This raises a significant issue about the quality of some iron-containing drugs sold in Ado Ekiti and Nigeria generally, highlighting the need for stringent regulation and monitoring of drugs by relevant regulatory authorities.
Okeke et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: